Market Overview

AI for Drug Discovery, Bio-Marker Development and Advanced R&D Landscape Overview 2018 / Q2 - ResearchAndMarkets.com

Share:

The "AI
for Drug Discovery, Bio-Marker Development and Advanced R&D Landscape
Overview 2018 / Q2"
report has been added to ResearchAndMarkets.com's
offering.

The second quarter of 2018 saw major changes, significant investments,
acquisitions, and the establishment of substantial joint ventures. This
serves as a stark reminder of how fast the AI for Drug Discovery,
Biomarker Development and Advanced R&D sector is advancing. Many trends
noted in our last report have continued and intensified, while other new
trends have emerged as well.

The report is structured in such a way as to meet the needs of different
kinds of readers and stakeholders according to their specific interests
and specialisation. It includes both broad chapters that describe the
underlying fundamentals of different areas of the AI for Drug Discovery
sphere, as well as chapters that give specific attention to industry
trends and developments, and chapters that provide comparative analyses
of companies, investors, R&D centers, IT, Tech and pharma corporations.

  • The report begins with several infographic MindMaps that deliver an
    understanding of the scope of the industry landscape at a single
    glance, including segmentation (by application and by region) of
    companies, investors and R&D centers.
  • The report's Executive Summary charts the major trends and significant
    developments that have occurred in the industry during the second
    quarter of 2018.
  • The report's Introduction (Background and Fundamentals of AI for Drug
    Discovery) lays the groundwork and background for an understanding of
    its more specialized chapters, offering a basic introduction to AI in
    Drug Discovery, the broader AI in healthcare industry, the specific
    factors that cause resistance to change in the BioPharma industry, and
    an introduction into the ways in which IT and Tech corporations are
    entering the sphere of AI in Drug Discovery.

Key Topics Covered:

AI for Drug Discovery Landscape Mind Maps

Executive Summary

Introduction: Background and Fundamentals of AI for Drug Discovery
Industry

Section I: AI for Drug Discovery Landscape Overview (Industry
Developments Q2 2018)

Chapter I: Landscape of AI for R&D and Drug Discovery Q2 2018

Chapter II: Regional Comparison: USA, UK, EU and Asia-Pacific

Chapter III: Trends of Investment and M&A Deals

Chapter IV: BioPharma Corporations Onboarding AI for Drug Discovery

Chapter V: IT & Tech Corporations Entering the AI for Drug Discovery
Space

Chapter VI: Government Initiatives

Chapter VII: Industry-Specific Media & Conferences

Section II: Novel Technologies & Trends (Industry Forecast 2019 2020)

Chapter VIII: Deep Learning in Drug Discovery

Chapter IX: Longevity Research (AI and Advanced R&D)

Chapter X: Next Generation AI, convergence with Blockchain and Digital
Medicine

Section III: Comparative Industry Analysis & Classification Framework
(Investor and M&A Guide)

Chapter XI: Classification/Ratings of AI for Advanced R&D and Drug
Discovery Companies

Chapter XII: 2010-2016 - Investment Rounds, M&A Deals and Notable Events

Chapter XIII: 2017 - Investment Rounds, M&A Deals and Notable Events

Chapter XIV: Q1 2018 - Investment Rounds, M&A Deals and Notable Events

Chapter XV: Q2 2018 - Investment Rounds, M&A Deals and Notable Events

Appendix / Profiles

100 Companies Applying AI for Drug Discovery and Advanced R&D

20 Leading R&D centers

15 BioPharma Corporations Using Artificial Intelligence for Drug
Discovery

15 Tech Corporations interested in Advanced AI applications in Healthcare

220 Investors in AI for Drug Discovery

For more information about this report visit https://www.researchandmarkets.com/research/nth668/ai_for_drug?w=4

View Comments and Join the Discussion!